HUP0004653A2 - Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására - Google Patents

Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására

Info

Publication number
HUP0004653A2
HUP0004653A2 HU0004653A HUP0004653A HUP0004653A2 HU P0004653 A2 HUP0004653 A2 HU P0004653A2 HU 0004653 A HU0004653 A HU 0004653A HU P0004653 A HUP0004653 A HU P0004653A HU P0004653 A2 HUP0004653 A2 HU P0004653A2
Authority
HU
Hungary
Prior art keywords
unit dosage
bone resorption
mammal
orally administering
inhibiting bone
Prior art date
Application number
HU0004653A
Other languages
English (en)
Inventor
Anastasia G. Daifotis
Arthur C. II. Santora
A. John Yates
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27517421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0004653(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority claimed from PCT/US1998/014796 external-priority patent/WO1999004773A2/en
Publication of HUP0004653A2 publication Critical patent/HUP0004653A2/hu
Publication of HUP0004653A3 publication Critical patent/HUP0004653A3/hu

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány biszfoszfonátok alkalmazására vonatkozik csontreszorpciógátlására szolgáló gyógyszerkészítmények előállítására, amely lehetővéteszi a gyomor-bél rendszerbeli káros hatások potenciáliselőfordulásának minimalizálását. A találmány továbbá agyógyszerkészítményekre és -készletekre is vonatkozik. A találmányértelmében valamely biszfoszfonátot alkalmaznak, amely lehetalendronát, cimadronát, clodronát, tiludronát, etidronát, ibadronát,rizedronát, piridronát, pamidronát, zoledronát, adott esetbenhisztamin H2 blokkolószerrel kombinálva. Ó
HU0004653A 1997-07-22 1998-07-17 The use of bisphosphonates for producing medicaments use ful for inhibiting bone resorption HUP0004653A3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption
US6041998A 1998-04-15 1998-04-15
PCT/US1998/014796 WO1999004773A2 (en) 1997-07-22 1998-07-17 Method for inhibiting bone resorption

Publications (2)

Publication Number Publication Date
HUP0004653A2 true HUP0004653A2 (hu) 2001-04-28
HUP0004653A3 HUP0004653A3 (en) 2002-12-28

Family

ID=27517421

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004653A HUP0004653A3 (en) 1997-07-22 1998-07-17 The use of bisphosphonates for producing medicaments use ful for inhibiting bone resorption

Country Status (2)

Country Link
HU (1) HUP0004653A3 (hu)
TW (1) TWI226833B (hu)

Also Published As

Publication number Publication date
HUP0004653A3 (en) 2002-12-28
TWI226833B (en) 2005-01-21

Similar Documents

Publication Publication Date Title
US5366965A (en) Regimen for treatment or prophylaxis of osteoporosis
Zahrowski Bisphosphonate treatment: an orthodontic concern calling for a proactive approach
AU761157B2 (en) Method for inhibiting dental resorptive lesions
Lee et al. Effects of bisphosphonate on the remodeling of rat sagittal suture after rapid expansion
AU1706102A (en) Use of bisphosphonates for pain treatment
HK1072539A1 (en) Use of bisphosphonates in the preparation of a medicament for the treatment of conditings of abnormally increased bone turnover
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
NZ515541A (en) Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis
JP3479780B2 (ja) 骨吸収を抑制する方法
CA2230690A1 (en) Administration of ketamine to manage pain and to reduce drug dependency
WO2001089494A3 (en) Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Rossini et al. Intramuscular clodronate therapy in postmenopausal osteoporosis
WO2004058235A3 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
CA2497353A1 (en) Method for preventing or reducing secondary fractures after hip fracture
HUP0004653A2 (hu) Biszfoszfonátok alkalmazása csontreszorpció gátlására szolgáló gyógyszerkészítmények előállítására
Fleisch Bisphosphonates
Tanwir et al. Bisphosphonates and the field of dentistry
Huffman Risedronate vs. etidronate for Pagent's disease of bone
TH25306A (th) วิธีของการใช้สำหรับยับยั้งการสูญเสียกระดูกและการลดคอเลสเทอรอลในซีรัม
AR017240A2 (es) COMPOSICIONES DE ÁCIDO ALENDRoNICO , SUS SALES O ESTERES

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO., INC., US

GB9A Succession in title

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO., INC., US; MERCK SHARP & DOHME CORP., US; SCHERING CORPORATION, US

HC9A Change of name, address

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): MERCK & CO., INC., US; MERCK SHARP & DOHME CORP., US; SCHERING CORPORATION, US

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished